このエントリーをはてなブックマークに追加
ID 37709
本文ファイル
著者
Ishioka, Shinichi
Hozawa, Soichiro
Maeda, Akihiro
Tamagawa, Kotaro
Watanabe, Tetsuya
Hiyama, Keiko
Yamakido, Michio
キーワード
Pranlukast
Cysteinyl leukotriene
Bronchial responsiveness
Aspirin-intolerant asthma
NDC
医学
抄録(英)
Cysteinyl leukotrienes (cysLTs) are considered to be the most important mediator involved in the pathogenesis of aspirin-intolerant asthma (AIA). However, the role of cysLTs in the baseline condition of the pathophysiology of AIA when not exposed to non-steroidal antiinflammatory drugs (NSAIDs) as well as that in the pathophysiology of aspirin-tolerant asthma remains to be elucidated. Therefore, we evaluated the effect of pranlukast, a potent, selective cysLT receptor antagonist, on bronchial responsiveness to methacholine, a non-specific stimulus, in 7 well-controlled aspirin-intolerant asthmatics receiving oral or inhaled corticosteroid treatment. Pranlukast was orally administered at a dose of 225 mg twice daily to all patients for 4 weeks, and the methacholine challenge test was performed before and after pranlukast treatment. The methacholine provocative concentration producing a 20% fall in forced expiratory volume in 1 second (PC₂₀-FEV₁) was calculated as an index of bronchial hyperresponsiveness (BHR). The geometric mean values of PC₂₀-FEV₁ significantly (p = 0.028) increased from 0.34 mg/dl to 0.61 mg/dl after pranlukast treatment. No significant differences were observed in the baseline values of forced vital capacity (FVC) or FEV1 before and after pranlukast treatment. These findings suggest that antagonism of endogenous cysLT by pranlukast may be responsible for the improvement of BHR to methacholine.
掲載誌名
Hiroshima Journal of Medical Sciences
49巻
2号
開始ページ
105
終了ページ
108
出版年月日
2000-06
出版者
Hiroshima University Medical Press
ISSN
0018-2052
NCID
言語
英語
NII資源タイプ
紀要論文
広大資料タイプ
学内刊行物(紀要等)
DCMIタイプ
text
フォーマット
application/pdf
著者版フラグ
publisher
部局名
医歯薬学総合研究科
他の一覧